| Literature DB >> 35049913 |
José X Soares1,2, Daniela R P Loureiro1,2,3, Ana Laura Dias2, Salete Reis1, Madalena M M Pinto2,3, Carlos M M Afonso2,3.
Abstract
The marine environment is an important source of specialized metabolites with valuable biological activities. Xanthones are a relevant chemical class of specialized metabolites found in this environment due to their structural variety and their biological activities. In this work, a comprehensive literature review of marine xanthones reported up to now was performed. A large number of bioactive xanthone derivatives (169) were identified, and their structures, biological activities, and natural sources were described. To characterize the chemical space occupied by marine-derived xanthones, molecular descriptors were calculated. For the analysis of the molecular descriptors, the xanthone derivatives were grouped into five structural categories (simple, prenylated, O-heterocyclic, complex, and hydroxanthones) and six biological activities (antitumor, antibacterial, antidiabetic, antifungal, antiviral, and miscellaneous). Moreover, the natural product-likeness and the drug-likeness of marine xanthones were also assessed. Marine xanthone derivatives are rewarding bioactive compounds and constitute a promising starting point for the design of other novel bioactive molecules.Entities:
Keywords: antimicrobial; antitumor; drug-like; marine products; molecular descriptors; natural products; xanthone
Mesh:
Substances:
Year: 2022 PMID: 35049913 PMCID: PMC8778107 DOI: 10.3390/md20010058
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of bioactive marine xanthones.
Figure 2Distribution of type (a) microorganism source (b) and activity (c) of the bioactive marine xanthones.
Figure 3Distribution of MW (a); Fsp3 (b); number of RBs (c); log P (d); TPSA (e); and log S (f) accordingly to the type of xanthone: “simple” (S, blue), “prenylated” (P, green), “hydroxanthone” (H, orange), O-heterocyclic (O, red), and complex (C, purple). Comparison between the values of Fsp3 carbons and MW (g); log P and MW (h); MW and TPSA (i); log P and log S (j); MW and log S (k); TPSA and log S (l).
Figure 4(a) KDE distribution plot NP-likeness score of synthetic molecules (SM), natural products (NP), and NP-likeness score of marine xanthones. (b) Distribution of NP-likeness score accordingly to the type of xanthone: “simple” (S, blue), “prenylated” (P, green), “hydroxanthone” (H, orange), “O-heterocyclic” (O, red), and “complex” (C, purple). (c) Heatmap of the compliance with rules of drug-likeness for the xanthone types. (d) Distribution of QED index accordingly to the type of xanthone.
Figure 5Distribution of MW (a); log S (b); log P (c); and fraction of sp3 carbons (d) accordingly to the biological activity reported for marine xanthones: antitumor (AT), antibacterial (AB), antiviral (AV), antifungal (AF), and antidiabetic (AD). Analysis of the functional group frequently found on antitumor (e); antibacterial (f); antiviral (g); antifungal (h), and antidiabetic (i) marine xanthones.
Antitumor marine xanthones.
| Name | Activity | Source | Ref. |
|---|---|---|---|
| Engyodontiumone B ( | U937 (IC50 = 55.5 µM); Hela (IC50 = 96.1 µM); | [ | |
| Sydowinin A ( | U937 (IC50 = 75.6 µM); Hela (IC50 ≥ 300 µM); | ||
| Sydowinin B ( | U937 (IC50 = 127.0 µM); Hela (IC50 ≥ 300 µM); | ||
| 2,6-Dihydroxy-3-methyl-9-oxoxanthene-8-carboxylic acid methyl ester ( | HEp-2 (IC50 = 8 µg mL−1); | Endophytic fungus (SK7RN3G1) isolated from mangrove collected in the South China Sea | [ |
| Monodictyxanthone ( | Hepa-1c1c7(Cyp1A inhibition (IC50 = 34.8 ± 7.4 µM); NAD(P)H:quinone reductase induction (CD ≥ 50 (1.4) µM, IC50 ≥ 50 µM) | [ | |
| 8-Hydroxy-6-methylxanthone-1-carboxylic acid ( | % Inhibitions on the cell proliferation at 10 μM: 22RV1 (71.3 ± 1.2%); C4-2B (60.7 ± 5.1%); | [ | |
| Methyl 8-hydroxy-6-methyl-9-oxo-9H-xanthene-1- carboxylate ( | % Inhibitions on the cell proliferation at 10 μM: 22RV1 (55.8 ± 3.0%); C4-2B (8.1 ± 20.6%); | ||
| Methyl 8-hydroxy-6-(hydroxymethyl)-9-oxo-9H-xanthene-1-carboxylate ( | % Inhibitions on the cell proliferation at 10 μM: 22RV1 (68.1 ± 1.9%); C4-2B (20.2 ± 0.1%); | ||
| Vertixanthone ( | % Inhibitions on the cell proliferation at 10 μM: 22RV1 (27.1 ± 6.9%); C4-2B (−0.1 ± 4.6%); | ||
| 8-(Methoxycarbonyl)-1-hydroxy-9-oxo-9H-xanthene-3-carboxylic acid ( | % Inhibitions on the cell proliferation at 10 μM: 22RV1 (63.9 ± 2.2%); C4-2B (12.2 ± 5.2%); | ||
| 3,8-Dihydroxy-6-methyl-9-oxo-9H-xanthene-1-carboxylate ( | % Inhibitions on the cell proliferation at 10 μM: 22RV1 (82.1 ± 0.9%); C4-2B (77.7 ± 0.5%); | ||
| Conioxanthone A ( | % Inhibitions on the cell proliferation at 10 μM: 22RV1 (36.8 ± 13.3%); C4-2B (3.3 ± 11.3%); | ||
| Questin ( | A549 (IC50 = 40.0 ± 0.3 µM); | [ | |
| Penixanacid A ( | HeLa (IC50 = 10.0 µM); BEL-7402 (IC50 = 30.6 µM); HEK-293 (IC50 = 28.5 µM); HCT-116 (IC50 = 19.0 µM); A-549 (IC50 = 16.9 µM) | [ | |
| Norlichexanthone ( | K562 (IC50 = 74.6 μM); A549 (IC50 = 64.6 μM); | [ | |
| Yicathin C ( | A549 (IC50 = 37.7 ± 0.3 µM) | [ | |
| A375-C5 (IC50 = 48.70 ± 4.24 µM); MCF-7 (IC50 = 98.93 ± 9.83 µM); NCI-H460 (IC50 = 79.83 ± 18.45 µM) | [ | ||
| Yicathin B ( | A375-C5 (IC50 = 47.70 ± 2.62 µM); MCF-7 (IC50 = 73.92 ± 2.28 µM); NCI-H460 (IC50 = 86.21 ± 2.30 µM) | ||
| 2-Hydroxy-6-formyl-vertixanthone ( | HepG2 (IC50 = 32.7 ± 0.9 µM) | [ | |
| 12- | A549 (IC50 = 25.2 ± 0.9 µM); HepG2 (IC50 = 42.3 ± 0.6 µM); HeLa (IC50 = 33.6 ± 0.7 µM) | ||
| Emodin ( | HeLa (IC50 = 27.1 ± 0.8 µM) | ||
| Engyodontiumone H ( | U937 (IC50 = 4.9 µM); Hela (IC50 = 24.8 µM); | [ | |
| Engyodontiumone C ( | U937 (IC50 = 218.4 µM); Hela (IC50 ≥ 300 µM); | ||
| Engyodontiumone D ( | U937 (IC50 = 208.6 µM); Hela (IC50 ≥ 300 µM); | ||
| Engyodontiumone E ( | U937 (IC50 = 15.9 µM); Hela (IC50 = 205.9 µM); | ||
| Engyodontiumone F ( | U937 (IC50 = 192.7 µM); Hela (IC50 ≥ 300 µM); | ||
| Engyodontiumone G ( | U937 (IC50 = 287.2 µM); Hela (IC50 ≥ 300 µM); | ||
| Globosuxanthone A ( | HCT-15 (IC50 = 10.7 µM); T-cell leukemia Jurkat cells (IC50 = 2.3 µM) | [ | |
| Monodictysin A ( | Hepa-1c1c7(Cyp1A inhibition IC50 ≥ 50 µM); NAD(P)H:quinone reductase induction (CD = 191.1 µM, IC50 ≥ 400 µM) | [ | |
| Monodictysin B ( | Hepa-1c1c7(Cyp1A inhibition IC50 = 23.3 ± 3.9 µM); NAD(P)H:quinone reductase induction (CD = 12.0 ± 4.8 µM, IC50 ≥ 50 µM) | ||
| Monodictysin C ( | Hepa-1c1c7(Cyp1A inhibition IC50 = 3.0 ± 0.7 µM); NAD(P)H:quinone reductase induction (CD = 12.8 ± 2.6 µM, IC50 ≥ 50 µM) | ||
| α-Diversonolic ester ( | % Inhibitions on the cell proliferation at 10 μM: 22RV1 (28.8 ± 10.3%); C4-2B (12.9 ± 12.6%); RWPE-1 (24.3 ± 3.3%) | [ | |
| β-Diversonolic ester ( | % Inhibitions on the cell proliferation at 10 μM: 22RV1 (40.2 ± 1.5%); C4-2B (2.8 ± 2.2%); RWPE-1 (10.3 ± 3.8%) | ||
| Penixanthone A ( | Weak cytotoxicity against H1975, MCF-7, K562, HL7702 at concentration of 30 μM. | [ | |
| AGI-B4 ( | K562 (IC50 = 6.97 µM); MCF-7 (IC50 = 11.7 µM); HeLa (IC50 = 1.39 µM); DU145 (IC50 = 2.69 µM); U937 (IC50 = 0.463 µM); H1975 (IC50 = 8.53 µM); SGC-7901 (IC50 = 9.43 µM); A549 (IC50 = 7.01 µM); MOLT-4 (IC50 = 5.26 µM); HL-60 (IC50 = 6.20 µM) | [ | |
| U937 (IC50 = 8.8 µM); Hela (IC50 = 60.0 µM); | [ | ||
| L5178Y (IC50 = 1.5 µM) | [ | ||
| Versicone G ( | NB4 (IC50 = 15.6 µM); HL-60 (IC50 = 21.7 µM); HeLa (IC50 = 16.9 µM) | [ | |
| Paeciloxanthone ( | HepG2 (IC50 = 1.08 µg mL−1) | [ | |
| Chaetoxanthone A ( | L6-cells (IC50 = 59.1 μg/mL) | [ | |
| Chaetoxanthone B ( | L6-cells (IC50 > 90 μg/mL) | ||
| Chaetoxanthone C ( | L6-cells (IC50 = 46.7 μg/mL) | ||
| Sterigmatocystin ( | Bel-7402 (IC50 = 96.53 µg mL−1); NCIH-460 (IC50 = 72.52 µg mL−1) | Fungal strain (isolate 1850) isolated from a leaf of | [ |
| A-549 (IC50 = 1.86 µg mL−1); SK-OV-3 (IC50 = 2.53 µg mL−1); SK-MEL-2 (IC50 = 1.22 µg mL−1); XF- 498 (IC50 = 2.75 µg mL−1); HCT-15 (IC50 = 4.61 µg mL−1) | [ | ||
| A-549 (IC50 = 11.25 μg mL−1); SK-OV-3 (IC50 = 17.36 μg mL−1); SK-MEL-2 (IC50 = 14.33 μg mL−1); XF-498 (IC50 = 15.12 μg mL−1); HCT-15 (IC50 ≥ 30 μg mL−1) |
| [ | |
| Aspergixanthone A ( | A-549 (IC50 = 1.8 µM) | [ | |
| Aspergixanthone C ( | MDA-MB-231 (IC50 = 3.3 µM); MCF-7 (IC50 = 2.8 µM); MGC-803 (IC50 = 3.6 µM); HeLa (IC50 = 2.9 µM); A-549 (IC50 = 3.2 µM) | ||
| Aspergixanthone F ( | MDA-MB-231 (IC50 = 9.8 µM); MCF-7 (IC50 = 2.7 µM); MGC-803 (IC50 = 3.6 µM); HeLa (IC50 = 1.7 µM); A-549 (IC50 = 1.1 µM) | ||
| 5-Methoxysterigmatocystin ( | A-549 (IC50 = 3.86 µM); HL-60 (IC50 = 5.32 µM) |
| [ |
| Epiremisporine B ( | K562 (IC50 = 16.6 µM); MCF-7(IC50 = 16.3 µM); SGC7901 (IC50 = 15.8 µM) | [ | |
| Dicerandrol C ( | MDA-MB-435 (IC50 = 44.10 ± 2.45 µM); HCT-116 (IC50 = 42.63 ± 2.90 µM); Calu-3 (IC50 = 36.52 ± 3.32 µM); Huh7 (IC50 ≥ 50 µM); MCF-10A (IC50 = 33.05 ± 2.74 µM) | [ | |
| Secalonic acid D ( | PANC-1 Glucose (−) (IC50 = 0.6 µM); PANC-1 Glucose (+) (IC50 ≥ 1000 µM) | [ | |
| U87 MG (IC50 = 5.64 µM); NCI-H1650 (IC50 = 4.93 µM); HT29 (IC50 = 1.46 µM)A498 (IC50 = 8.88 µM); HL-60 (IC50 = 0.41 µM) | [ | ||
| SK- HEP (IC50 = 1.504 µM); Hela (IC50 = 1.322 µM); A549 (IC50 = 1.625 µM); SK-MES-1 (IC50 = 1.314 µM); SPC-A1 (IC50 = 1.679 µM); 95D (IC50 = 1.003 µM); Jeko-1 (IC50 = 0.915 µM); Raji (IC50 = 0.955 µM); U937 (IC50 = 1.119 µM); A375 (IC50 = 1.598 µM); HFF (IC50 = 24.1 µM); H22 (IC50 = 1.007µM) | [ | ||
| Versixanthone G ( | HL-60 (IC50 = 13.4 µM); K562 (IC50 = 20.9 µM); A549 (IC50 = 17.8 µM); H1975 (IC50 = 9.8 µM); MGC803 (IC50 = 4.6 µM); HEK293 (IC50 ≥ 50 µM); HO-8910 (IC50 = 9.6 µM); HCT-116 (IC50 = 16.2 µM) | [ | |
| Versixanthone H ( | HL-60 (IC50 = 6.9 µM); K562 (IC50 = 22.1 µM); A549 (IC50 = 19.2 µM); H1975 (IC50 = 5.3 µM); MGC803 (IC50 = 6.2 µM); HEK293 (IC50 ≥ 50 µM); HO-8910 (IC50 = 6.9 µM); HCT-116 (IC50 = 15.2 µM) | ||
| Versixanthone I ( | HL-60 (IC50 = 27.8 µM); K562 (IC50 ≥ 50.0 µM); A549 (IC50 ≥ 50.0 µM); H1975 (IC50 ≥ 50.0 µM); HEK293 (IC50 ≥ 50 µM); HO-8910 (IC50 ≥ 50.0 µM); HCT-116 (IC50 ≥ 50.0 µM) | ||
| Versixanthone J ( | HL-60 (IC50 = 47.3 µM); K562 (IC50 ≥ 50.0 µM); A549 (IC50 ≥ 50.0 µM); H1975 (IC50 ≥ 50.0 µM); HEK293 (IC50 ≥ 50 µM); HO-8910 (IC50 ≥ 50.0 µM); HCT-116 (IC50 ≥ 50.0 µM) | ||
| Versixanthone K ( | HL-60 (IC50 = 49.5 µM); K562 (IC50 ≥ 50.0 µM); A549 (IC50 ≥ 50.0µM); H1975 (IC50 = 49.5 µM); MGC803 (IC50 ≥ 50.0µM); HEK293 (IC50 ≥ 50 µM); HO-8910 (IC50 ≥ 50.0 µM); HCT-116 (IC50 ≥ 50.0 µM) | ||
| Versixanthone L ( | HL-60 (IC50 = 0.5 µM); K562 (IC50 = 1.1 µM); A549 (IC50 = 1.6 µM); MGC803 (IC50 = 1.1 µM); HO-8910 (IC50 = 1.5 µM); HCT-116 (IC50 = 1.2 µM) | ||
| Versixanthone M ( | HL-60 (IC50 = 0.9 µM); K562 (IC50 = 0.4 µM); A549 (IC50 = 11.7 µM); H1975 (IC50 = 3.5 µM); MGC803 (IC50 = 0.9 µM); HO-8910 (IC50 = 1.4 µM); line HCT-116 (IC50 = 0.5 µM) | ||
| Citreamicin ε A ( | HeLa (IC50 = 0.032 ± 0.0062 µM); HepG2 (IC50 = 0.079 ± 0.031 µM) | [ | |
| Citreamicin ε B ( | HeLa (IC50 = 0.031 ± 0.0081 µM); HepG2 (IC50 = 0.10 ± 0.0053 µM) | ||
| Acredinone C ( | Inhibited the RANKL- induced formation of TRAP+-MNCs in a dose-dependent manner without any cytotoxicity up to 10 μM | [ | |
| Phomolactonexanthone A ( | Calu-3 (IC50 = 43.45 ± 2.51 µM) | [ | |
| Deacetylphomoxanthone C ( | HCT-116 (IC50 = 44.06 ± 3.29 µM); Calu-3 (IC50 = 43.35 ± 2.09µM) | ||
| Dicerandrol A ( | MDA-MB-435 (IC50 = 3.03 ± 0.12 µM); HCT-116 (IC50 = 2.64 ± 0.03 µM); Calu-3 (IC50 = 1.76 ± 0.02 µM); Huh7 (IC50 = 4.19 ± 0.08 µM); MCF-10A (IC50 = 28.32 ± 3.57µM) | ||
| Dicerandrol B ( | MDA-MB-435 (IC50 = 8.65 ± 0.66 µM); HCT-116 (IC50 = 3.94 ± 0.39µM); Calu-3 (IC50 = 4.10 ± 0.08 µM); Huh7 (IC50 = 30.37 ± 1.10 µM); MCF-10A (IC50 = 8.14 ± 1.27 µM) | ||
| Deacetylphomoxanthone B ( | MDA-MB-435 (IC50 = 14.40 ± 1.18 µM); HCT-116 (IC50 = 7.12 ± 0.70 µM); Calu-3 (IC50 = 4.14 ± 0.02 µM); Huh7 (IC50 = 29.20 ± 1.19 µM) | ||
| Penexanthone A ( | MDA-MB-435 (IC50 = 7.90 ± 0.58µM); HCT-116 (IC50 = 6.92 ± 0.38 µM); Calu-3 (IC50 = 6.44 ± 0.86 µM); Huh7 (IC50 = 42.82 ± 3.58 µM); MCF-10A (IC50 = 16.13 ± 1.57 µM) | ||
| 4,4′-bond Secalonic acid D ( | SK- HEP (IC50 = 1.342 µM); Hela (IC50 = 0.827 µM); A549 (IC50 = 1.353 µM); SK-MES-1 (IC50 = 0.640 µM); SPC-A1 (IC50 = 1.205 µM); 95D (IC50 = 0.978 µM); Jeko-1 (IC50 = 0.705 µM); Raji (IC50 = 0.484 µM); U937 (IC50 = 0.960 µM); A375 (IC50 = 1.085 µM); HFF (IC50 = 26.6 µM); H22 (IC50 = 1.211 µM) | [ | |
| Phomoxanthone A ( | HL-60 (cytotoxic at 0.1 to 0.01 μg mL−1) | [ | |
| JBIR-97 ( | HeLa (IC50 = 11 µM); ACC-MESO-1 (IC50 = 31 µM) | [ | |
| JBIR-98 ( | HeLa (IC50 = 17 µM); ACC-MESO-1 (IC50 = 63 µM) | ||
| JBIR-99 ( | HeLa (IC50 = 17 µM); ACC-MESO-1 (IC50 = 59 µM) | ||
| Buanmycin ( | A549 (IC50 = 1.7 µM); HCT116 (IC50 = 0.9 µM); SNU638 (IC50 = 0.8 µM); SK-HEP1 (IC50 = 1.9 µM); MDA-MB231 (IC50 = 1.2 µM) | [ | |
| A549 (IC50 = 0.8 µM); HeLa (IC50 = 0.9 µM) | [ | ||
| Chrysoxanthone A ( | U87 MG (IC50 = 22.6 µM); NCI-H1650 (IC50 = 42.2 µM); HT29 (IC50 = 41.8 µM); A498 (IC50 = 28.5 µM); HL-60 (IC50 = 37.2 µM) | [ | |
| Chrysoxanthone B ( | U87 MG (IC50 ≥ 50 µM); NCI-H1650 (IC50 ≥ 50 µM); HT29 (IC50 = 30.8 µM); A498 (IC50 ≥ 50 µM); HL-60 (IC50 = 16.2 µM) | ||
| Chrysoxanthone C ( | U87 MG (IC50 = 47.0 µM); NCI-H1650 (IC50 ≥ 50 µM); HT29 (IC50 = 43.2 µM); A498 (IC50 ≥ 50 µM); HL-60 (IC50 = 22.7 µM) | ||
| Ukixanthomycin A ( | A549 (IC50 ≥ 200 µM); HeLa (IC50 ≥ 200 µM) | [ |
IC50: half maximum inhibitory concentration; CD: concentration required to double quinone reductase specific activity.
Figure 6The number of antitumor marine xanthone and the most frequently assayed tumor cell lines. Dark purple bar represents the total count of the assayed xanthones. Light purple bar represents the count of xanthones with IC50 lower than 10 µM.
Antibacterial marine xanthone.
| Name | Activity | Source | Ref. |
|---|---|---|---|
| Sydowinin B ( | [ | ||
| 1,4,7-Trihydroxy-6-methylxanthone ( | [ | ||
| 1,4,5-Trihydroxy-2-methylxanthone ( | |||
| Norlichexanthone ( | [ | ||
| Yicathin C ( | [ | ||
| Yicathin B ( | |||
| Fischexanthone ( | [ | ||
| Methyl (2-chloro-l,6-dihydroxy-3-methylxanthone)-8-carboxylate ( | [ | ||
| Methyl (4- chloro-l,6-dihydroxy-3-methylxanthone)-8-carboxylate ( | |||
| 2-Hydroxy-6-formyl-vertixanthone ( | MRSA (ATCC 43300) (MIC = 16.3 ± 0.9 µg mL−1); MRSA (CGMCC 1.12409) (MIC = 16.1 ± 0.5 µg mL−1) | [ | |
| 12- | MRSA (ATCC 43300) (MIC = 32.6 ± 0.8 µg mL−1); MRSA (CGMCC 1.12409) (MIC = 31.8 ± 0.8 µg mL−1) | ||
| Emodin ( | |||
| Aspergillusone A ( | MRSA (ATCC 43300) (MIC = 32.2 ± 0.3 µg mL−1); MRSA (CGMCC 1.12409) (MIC = 32.4 ± 0.1 µg mL−1) | ||
| BCG ( | [ | ||
| Chalaniline B ( | Percent (%) growth of treated bacteria: | Endophytic ascomycete with | [ |
| Engyodontiumone H ( | [ | ||
| Aspergillusone B ( | |||
| AGI-B4 ( | |||
| Deep sea-derived fungus | [ | ||
| Blennolide A ( | [ | ||
| Blennolide B ( | |||
| Paeciloxanthone ( | [ | ||
| Stergimatocystin ( |
| [ | |
| Hemi-acetal sterigmatocystin ( | [ | ||
| Acyl-hemiacetal sterigmatocystin ( | |||
| 5-Methoxydihydrosterigmatocystin ( | |||
| Emerixanthone E ( | [ | ||
| Emerixanthone A ( | [ | ||
| Emerixanthone C ( | |||
| Varixanthone ( | [ | ||
| Oxisterigmatocystin C ( | [ | ||
| Aspergixanthone G ( | [ | ||
| Aspergixanthone H ( | |||
| Dicerandrol C ( | [ | ||
| Secalonic acid D ( | [ | ||
| [ | |||
| JBIR-97/98 ( | [ | ||
| Engyodontochone A ( | |||
| JBIR-99 ( | |||
| Engyodontochone B ( | |||
| Microluside A ( | [ | ||
| Citreamicin θ A ( | [ | ||
| Citreamicin θ B ( | |||
| Citreaglycon A ( | |||
| Dehydrocitreaglycon A ( | |||
| Penicillixanthone A ( | [ | ||
| IB-00208 ( | [ | ||
| Buanmycin ( | [ | ||
| [ | |||
| Secalonic acid A ( | [ | ||
| Secalonic acid B ( | [ | ||
| [ | |||
| Neocitreamicin I ( | [ | ||
| Neocitreamicin II ( | |||
| Citreamicin α ( | Culture LL-E19085 was isolated from a soil sample collected at Lake Manyara | [ | |
| Chrysoxanthone A ( | [ | ||
| Chrysoxanthone B ( | |||
| Chrysoxanthone C ( | |||
| Ukixanthomycin A ( | [ |
MIC: Minimum inhibitory concentration, IC50: Half maximal inhibitory concentration. A. baumannii: Acinetobacter baumannii; A. hydrophila: Aeromonas hydrophila; B. anthracis: Bacillus anthracis; B. cereus: Bacillus cereus; B. fragilis: Bacteroides fragilis; B. megaterium: Bacillus megaterium; B. subtilis: Bacillus subtilis; B. thetaiotaomicron: Bacteroides thetaiotaomicron; C. difficile: Clostridium difficile; C. perfringens: Clostridium perfringens; E. coli: Escherichia coli; E. aerogenes: Enterobacter aerogenes; E. faecalis: Enterococcus faecalis; E. faecium: Enterococcus faecium; K. pneumoniae: Klebsiella pneumoniae; K. rhizophila: Kocuria rhizophila; M. bovis: Mycobacterium bovis; M. luteus: Micrococcus luteus; M. tuberculosis: Mycobacterium tuberculosis; MRSA: Methicillin-resistant Staphylococcus aureus; P. acnes: Propionibacterium acnes; P. aeruginosa: Pseudomonas aeruginosa; P. hauseri: Proteus hauseri; P. nigrifaciens: Pseudoalteromonas nigrifaciens; S. aureus: Staphyloccocus aureus; S. enterica: Salmonella enterica; S. epidermidis: Staphylococcus epidermidis; S. haemolyticus: Staphylococcus haemolyticus; S. pneumoniae: Streptococcus pneumoniae; S. saprophyticus: Staphylococcus saprophyticus; S. typhi: Salmonella typhi; S. ventriculi: Sarcina ventriculi; V. alginolyticus: Vibro alginolyticus; V. harveyi: Vibro harveyi; V. parahaemolyticus: Vibro parahaemolyticus; V. rotiferianus: Vibro rotiferianus; V. vulnificus: Vibro vulnificus.
Figure 7(a) The number of antibacterial marine xanthones evaluated against Gram-positive and Gram-negative bacteria. Dark blue bar represents the total count of the assayed xanthones. Light blue bar represents the count of xanthones with MIC lower than 4 µg mL−1. (b) The bacteria that were assayed for antibacterial activity. Dark blue bar represents the total count of the assayed xanthones. Light blue bar represents the count of xanthones with MIC lower than 4 µg mL−1.
Antifungal marine xanthone.
| Name | Activity | Source | Ref. |
|---|---|---|---|
| Norlichexanthone ( | [ | ||
| [ | |||
| Yicathin C ( | [ | ||
| Fischexanthone ( | [ | ||
| 2,3,6,8-Tetrahydroxy-1-methylxanthone ( | [ | ||
| Dimethyl 8-methoxy-9-oxo- 9H-xanthene-1, 6-dicarboxylate ( | [ | ||
| 1-Hydroxy-6-methyl-8-(hydroxymethyl)xanthone ( | [ | ||
| 4-Chlorofischexanthone ( | [ | ||
| 8-Hydroxy-3-methyl-9-oxo-9H-xanthene-1-carboxylic acid methyl ether ( | Co-culture broth of mangrove fungi (strain No. K38 and E33) collected in the South China Sea | [ | |
| Globosuxanthone A ( | [ | ||
| Blennolide A ( | [ | ||
| Blennolide B ( | |||
| Paeciloxanthone ( | [ | ||
| Versicone A ( | C. a | [ | |
| Versicone B ( | |||
| Versicone C ( | |||
| Versicone D ( | |||
| Emerixanthone D ( | [ | ||
| Buanmycin ( | [ | ||
| [ | |||
| Secalonic acid A ( | [ | ||
| Secalonic acid B ( | [ | ||
| Ukixanthomycin A ( | [ |
MIC: Minimum inhibitory concentration, IC50: Half maximal inhibitory concentration. A. fumigatus: Aspergillus fumigatus; A. niger: Aspergillus niger; C. albicans: Candida albicans; C. acutatum: Colletotrichum acutatum; C. glocosporioides: Colletotrichum glocosporioides; C. lagenarium: Colletotrichum lagenarium; C. lunata: Curvularia lunata; C. musae: Calletotrichum musae; E. repens: Eurotium repens; F. graminearum: Fusarium graminearum; F. oxysporum: Fusarium oxysporum; G. musae: Gloeosporium musae; M. oryzae: Magnaporthe oryzae; M. violaceum: Microbotryum violaceum; P. cichoralearum: Peronophthora cichoralearum; R. solani: Rhizoctonia solani; U. violacea: Ustilago violacea.
Antiviral marine xanthone.
| Name | Activity | Source | Ref. |
|---|---|---|---|
| Norlichexanthone ( | EV71 (IC50 = 40.3 μM) | [ | |
| HIV-1-RT (82.9% inhibition at 66 μg mL−1) | [ | ||
| 2,3,6,8-Tetrahydroxy-1-methylxanthone ( | HIV-1-RT (82.2% inhibition at 66 μg mL−1) | ||
| 3,8-Dihydroxy-6-methyl-9- oxo-9H-xanthene-1-carboxylate ( | H1N1 (A/Puerto Rico/8/34 H274Y) (IC50 = 9.40 ± 1.96 µM); H1N1 (A/FM-1/1/47) (IC50 = 4.80 ± 1.28 µM); H3N2 (A/Aichi/2/68) (IC50 = 5.12 ± 1.49 µM) | [ | |
| Methyl-(2-chloro-l,6-dihydroxy-3-methylxanthone)-8-carboxylate ( | H1N1 (IC50 = 133.4 µM); HSV-1 (IC50 = 55.5 µM); HSV-2 (IC50 = 175.5 µM) | [ | |
| Methyl-(4-chloro-l,6-dihydroxy-3-methylxanthone)-8-carboxylate ( | H1N1 (IC50 = 44.6 µM); HSV-1 (IC50 = 21.4 µM); HSV-2 (IC50 = 76.7 µM) | ||
| Methyl-(4-chloro-6-hydroxy-1-methoxy-3-methylxanthone)-8-carboxylate | H1N1 (IC50 ≥ 200 µM); HSV-1 (IC50 = 139.4 µM); HSV-2 (IC50 ≥ 200 µM) | ||
| Methyl-(6-hydroxy-1-methoxy-3-methylxanthone)-8-carboxylate ( | H1N1 (IC50 ≥ 200 µM); HSV-1 (IC50 = 157.7 µM); HSV-2 (IC50 = 163.3 µM) | ||
| 4-Chloro-1,6-dihydroxy-3-methylxanthone-8-carboxylic acid ( | H1N1 (IC50 ≥ 200 µM); HSV-1 (IC50 = 183.3 µM); HSV-2 (IC50 ≥ 200 µM) | ||
| 2,4-Dichloro-1,6-dihydroxy-3-methylxanthone-8-carboxylic acid ( | H1N1 (IC50 ≥ 200 µM); HSV-1 (IC50 = 144.4 µM); HSV-2 (IC50 ≥ 200 µM) | ||
| Methyl-(l,6-dihydroxy-3-methylxanthone)-8-carboxylate ( | H1N1 (IC50 = 140.4 µM); HSV-1 (IC50 = 75.7 µM); HSV-2 (IC50 = 95.4 µM) | ||
| 2-Hydroxy-1-(hydroxymethyl)-8-methoxy-3-methyl-9H-xanthen-9- one ( | H1N1 (A/PuertoRico/8/34) (IC50 = 4.70 ± 1.11 µM); H1N1 (A/FM-1/1/47) (IC50 = 4.04 ± 0.58 µM) | [ | |
| 2-Hydroxy-1-(hydroxymethyl)-7,8-dimethoxy-3-methyl-9H- xanthen-9-one ( | H1N1 (A/PuertoRico/8/34) (IC50 = 2.17 ± 1.39 µM) | ||
| Sterigmatocystin A ( | HSV-2 (IC50 = 47.11 µM) | [ | |
| Sterigmatocystin B ( | HSV-2 (IC50 = 39.45 µM) | ||
| Sterigmatocystin C ( | HSV-2 (IC50 = 38.73 µM) | ||
| Asperxanthone ( | Tobacco mosaic virus: inhibitory rate 62.9% | [ | |
| Epiremisporine B ( | EV71 (IC50 = 19.8 μM); H3N2 (IC50 = 24.1 μM) | [ | |
| Penicillixanthone A ( | HIV-1 (SF162) (10 μM, 90.86 ± 0.82%); HIV-1 (CCR5-tropic) (IC50 = 0.36 µM); HIV-1 (CXCR4-tropic) (IC50 = 0.26 µM) | [ |
EV71: Enterovirus 71; H1N1: Influenza A virus subtype H1N1; H3N2: Influenza A virus subtype H3N2; HIV: human immunodeficiency virus; HSV: herpes simplex virus; IC50: Half maximal inhibitory concentration; RT: Reverse-transcriptase.
Antidiabetic marine xanthone.
| Name | Activity | Source | Ref. |
|---|---|---|---|
| Chrysoxanthone ( | α-Glucosidase inhibition (IC50 = 0.04 mM) | [ | |
| Staprexanthone A ( | Pancreatic β-cell number (zebrafish model): ~40 at 10 µM | [ | |
| Staprexanthone B ( | Pancreatic β-cell number (zebrafish model): 40 at 10 µM | ||
| Staprexanthone C ( | Pancreatic β-cell number (zebrafish model): ~35 at 10 µM | ||
| Staprexanthone D ( | Pancreatic β-cell number (zebrafish model): ~35 at 10 µM | ||
| Staprexanthone E ( | Pancreatic β-cell number (zebrafish model): ~40 at 10 µM | ||
| Austocystin J ( | Inhibitory effect against phosphatases: SHP1 (IC50 = 15 μM); MEG2 (IC50 = 77 μM) | [ | |
| Austocystin K ( | Inhibitory effect against phosphatases: TCPTP (IC50 = 16 μM); SHP1 (IC50 = 3.8 μM) | ||
| Austocystin L ( | Inhibitory effect against phosphatases: TCPTP (IC50 = 12 μM); SHP1 (IC50 = 20 μM); CDC25B (IC50 = 24 μM) | ||
| Austocystin M ( | Inhibitory effect against phosphatases: TCPTP (IC50 = 12 μM); SHP2 (IC50 = 9.5 μM); PTP1B (IC50 = 4.6 μM) | ||
| Austocystin N ( | Inhibitory effect against phosphatases: SHP1 (IC50 = 17 μM) | ||
| Austocystin I ( | Inhibitory effect against phosphatases: MEG2 (IC50 = 16 μM); CDC25B (IC50 = 19 μM) | ||
| Austocystin F ( | Inhibitory effect against phosphatases: SHP1 (IC50 = 6.7 μM); MEG2 (IC50 = 2.1 μM); CDC25B (IC50 = 6.7 μM); CD45 (IC50 = 20 μM) | ||
| Austocystin A ( | Inhibitory effect against phosphatases: TCPTP (IC50 = 19 μM); MEG2 (IC50 = 8.1 μM); CDC25B (IC50 = 16 μM) | ||
| Austocystin H ( | Inhibitory effect against phosphatases: TCPTP (IC50 = 3.0 μM); SHP1 (IC50 = 1.3 μM); SHP2 (IC50 = 1.3 μM); MEG2 (IC50 = 0.60 μM); PTP1B (IC50 = 0.90 μM); CDC25B (IC50 = 1.3 μM); CD45 (IC50 = 14 μM) | ||
| Austocystin B ( | Inhibitory effect against phosphatases: TCPTP (IC50 = 8.8 μM); SHP2 (IC50 = 2.0 μM); MEG2 (IC50 = 1.3 μM); PTP1B (IC50 = 1.8 μM); CDC25B (IC50 = 1.3 μM) | ||
| Austocystin D ( | Inhibitory effect against phosphatases: PTP1B (IC50 = 1.7 μM) | ||
| 8- | Inhibitory effect against phosphatases: TCPTP (IC50 = 11 μM); SHP1 (IC50 = 5.5 μM); MEG2 (IC50 = 4.6 μM); CDC25B (IC50 = 4.9 μM); CD45 (IC50 = 6.1 μM) | ||
| (1′ R,2′ R)-compound V ( | Inhibitory effect against phosphatases: TCPTP (IC50 = 19 μM); SHP1 (IC50 = 6.9 μM); MEG2 (IC50 = 4.2 μM) |
IC50: Half maximal inhibitory concentration.
Antioxidant marine xanthone.
| Name | Activity | Source | Ref. |
|---|---|---|---|
| 1,4,7-Trihydroxy-6-methylxanthone ( | DPPH (IC50 = 6.92 µg mL−1); | [ | |
| 1,4,5-Trihydroxy-2-methylxanthone ( | DPPH (IC50 = 1.23 µg mL−1); | ||
| Norlichexanthone ( | DPPH (% Scavenging effect: 6.2% at 25.0 μg mL−1; 12.9% at 50 μg mL−1; 25.3% at 100 μg mL−1; 90.6% at 500 μg mL−1) | [ | |
| 2,3,6,8-Tetrahydroxy-1-methylxanthone ( | DPPH (% Scavenging effect: 94.7% at 25.0 μg mL−1; 94.8% at 50 μg mL−1; 95.2% at 100 μg mL−1; 95.4% at 500 μg mL−1) | ||
| Arthone C ( | DPPH (IC50 = 16.9 µM); | [ | |
| 2,3,4,6,8-Pentahydroxy-1-methylxanthone ( | DPPH (IC50 = 22.1 µM); | ||
| Sterigmatocystin ( | ABTS (0.65 ± 0.13 TEAC values) | [ | |
| Oxisterigmatocystin C ( | ABTS (1.16 ± 0.18 TEAC values) | ||
| Oxisterigmatocystin D ( | ABTS (0.55 ± 0.13 TEAC values) |
ABTS: (2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)); DPPH: (2,2-diphenyl-1-picryl-hydrazyl-hydrate); IC50: Half maximal inhibitory concentration; TEAC: Trolox equivalents antioxidant capacity.
Anti-inflammatory marine xanthone.
| Name | Activity | Source | Ref. |
|---|---|---|---|
| Norlichexanthone ( | COX-2 (IC50 = 34.3 µM) | [ | |
| Yicathin C ( | NO inhibition (27.0 ± 3.2%); NF-κB inhibition (56.8 ± 5.7%) | [ | |
| IL-6 cytokine % at 1 µM: 78.37 ± 7.78% | [ | ||
| Yicathin B ( | IL-6 cytokine % at 10 µM: 95.65 ± 17.21% | ||
| NO inhibition (35.3 ± 3.9%); NF-κB inhibition (81.2 ± 8.3%) | [ | ||
| 1,3,6-trihydroxy-8-methylxanthone ( | COX-2 (IC50 = 12.2 µM) | [ | |
| Calyxanthone ( | NO inhibition (17.6 ± 5.1) | [ | |
| Yicathin A ( | NO inhibition (23.7 ± 4.8%); NF-κB inhibition (13.0 ± 9.8%) | ||
| Euroanthone A ( | NO inhibition (42.2 ± 2.3%); NF-κB inhibition (68.8 ± 7.0%) | ||
| Euroanthone B ( | NO inhibition (23.4 ± 3.3%); NF-κB inhibition (52.3 ± 10.6%) |
COX: Cyclooxygenase; IC50: Half maximal inhibitory concentration; NF-κΒ: factor nuclear kappa B; NO: nitric oxide.
Marine xanthone with miscellaneous biological activities.
| Name | Activity | Source | Ref. |
|---|---|---|---|
| Sydowinin A ( | Immunosuppressive: | [ | |
| Sydowinin B ( | Immunosuppressive: | ||
| Methyl 8-hydroxy-6-methyl-9-oxo-9H-xanthene-1- carboxylate ( | Immunosuppressive: | ||
| Conioxanthone A ( | Immunosuppressive: | ||
| Pinselin ( | Immunosuppressive: | ||
| Epiremisporine B ( | Immunosuppressive: | ||
| Remisporine B ( | Immunosuppressive: | ||
| Paeciloxanthone ( | Anti-Alzheimer: | [ | |
| Chaetoxanthone A ( | Antiprotozoal: | [ | |
| Chaetoxanthone B ( | Antiprotozoal: | ||
| Chaetoxanthone C ( | Antiprotozoal: | ||
| Aspergixanthone A ( | Against aquatic pathogens: | [ | |
| Sterigmatocystin A ( | Angiogenesis: | [ | |
| Aspergixanthone I ( | Against aquatic pathogens: | [ | |
| Aspergixanthone J ( | Against aquatic pathogens: | ||
| Aspergixanthone K ( | Against aquatic pathogens: | ||
| 15-Acetyl tajixanthone hydrate ( | Against aquatic pathogens: | ||
| Tajixanthone hydrate ( | Against aquatic pathogens: | ||
| 16-Chlorotajixanthone ( | Against aquatic pathogens: | ||
| Isosecosterigmatocystin ( | Against aquatic pathogens: | [ |
Con A: Concanavalin A; Ed. ictaluri: Edwardsiella ictaluri; IC50: Half maximal inhibitory concentration; MIC: Minimum inhibitory concentration, L. donovani: Leishmania donovani; LPS: Lipopolysaccharide; T. brucei: Trypanosoma brucei; T. cruzi: Trypanosoma cruzi; V. alginolyticus: Vibrio alginolyticus; V. anguillarum: Vibrio anguillarum; V. parahemolyticus: Vibrio parahemolyticus.